Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 2/20 | 0.32 |
| ▸ | ARG2 | P78540 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841870 | 0.94 | TSHR (0.33) | TSHRTDP1 | |
| SCHEMBL13407596 | 0.86 | — | — | |
| SCHEMBL866725 | 0.86 | KCNH2 (0.31) | — | |
| SCHEMBL3217467 | 0.83 | TSHR (0.31) | TSHRTDP1 | |
| SCHEMBL678643 | 0.82 | SIGMAR1 (0.38) | TSHRTDP1ARG1ARG2SIGMAR1 | |
| SCHEMBL842083 | 0.82 | KCNH2 (0.42) | — | |
| SCHEMBL21612998 | 0.82 | TDP1 (0.33) | TDP1 | |
| SCHEMBL13656279 | 0.82 | CYP1A2 (0.47) | ARG1ARG2 | |
| SCHEMBL8361776 | 0.80 | SIGMAR1 (0.46) | ARG1ARG2SIGMAR1 | |
| SCHEMBL20202518 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043602-B2 | Fendiline derivatives | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-11834451-B2 | Compositions and methods for inhibiting virus protein 2C activity and for preventing and treating non-polio enterovirus infection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-11-23 | — | — | US | disclosed |
| US-20230348487-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | GUANGZHOU SALUSTIER BIOSCIENCES CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348487-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | GUANGZHOU SALUSTIER BIOSCIENCES CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| WO-2023098832-A1 | PYRIDOPYRIMIDINE DERIVATIVES SERVING AS SMALL GTP ENZYME KRAS MUTATION INHIBITORS | 思路迪生物医药(上海)有限公司 | 2023-06-08 | — | — | WO | disclosed |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | Regeneran Pharmaceuticals, Inc. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-7205313-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-7157582-B2 | Selective iGluR5 receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| WO-2003087057-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | TSHR 78/4885TDP1 4269/4885ARG1 145/4885 |
| US-12043602-B2 | Fendiline derivatives | CYP11B2, CYP3A7, CYP4F2 | TSHR 346/4885TDP1 1227/4885ARG1 1679/4885 |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | TSHR 3063/4885TDP1 522/4885ARG1 3734/4885 |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | ASGR1, CUTA, SRPRA | TSHR 22/4885TDP1 4412/4885ARG1 2420/4885 |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | KIT, PRKCH, PRKCE | TSHR 3111/4885TDP1 2495/4885ARG1 1775/4885 |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | ASGR1, CUTA, SRPRA | TSHR 22/4885TDP1 4412/4885ARG1 2420/4885 |
| US-20070105852-A1 | Thiophene and furan compounds | PSEN2, PSEN1, TPMT | TSHR 980/4885TDP1 287/4885ARG1 4621/4885 |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | TSHR 315/4885TDP1 1306/4885ARG1 142/4885 |
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | PCK1, PDK2, PDK1 | TSHR 3270/4885TDP1 1041/4885ARG1 2384/4885 |
| US-11834451-B2 | Compositions and methods for inhibiting virus protein 2C activity and for preventing and treating non-polio enterovirus infection | GTF3C3, VDAC3, GTF3C5 | TSHR 4249/4885TDP1 3689/4885ARG1 4859/4885 |
| US-20230348487-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | JAK3, JAK2, JAK1 | TSHR 3318/4885TDP1 1325/4885ARG1 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.